Christopher Brett Primiano Sells 10,000 Shares of Karyopharm Therapeutics Inc (KPTI) Stock
Karyopharm Therapeutics Inc (NASDAQ:KPTI) EVP Christopher Brett Primiano sold 10,000 shares of the stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $18.90, for a total value of $189,000.00. Following the completion of the sale, the executive vice president now owns 7,881 shares of the company’s stock, valued at $148,950.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
KPTI stock opened at $18.60 on Thursday. Karyopharm Therapeutics Inc has a fifty-two week low of $9.00 and a fifty-two week high of $21.71.
Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Tuesday, August 7th. The company reported ($0.60) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.21. The firm had revenue of $19.89 million for the quarter, compared to analyst estimates of $5.97 million. analysts anticipate that Karyopharm Therapeutics Inc will post -3.17 earnings per share for the current fiscal year.
Several equities research analysts have issued reports on KPTI shares. HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of Karyopharm Therapeutics in a report on Wednesday, August 29th. Zacks Investment Research upgraded Karyopharm Therapeutics from a “hold” rating to a “buy” rating and set a $21.00 price target for the company in a report on Wednesday, July 25th. Wedbush downgraded Karyopharm Therapeutics from an “outperform” rating to a “neutral” rating and lowered their price target for the stock from $20.00 to $19.00 in a report on Thursday, May 24th. ValuEngine upgraded Karyopharm Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 2nd. Finally, Robert W. Baird restated a “buy” rating and issued a $25.00 price target on shares of Karyopharm Therapeutics in a report on Wednesday, August 8th. Two investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $22.90.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.
See Also: What are the Benefits of Index Funds?
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.